Press Releases

Celleron Therapeutics announces MHRA Clinical Trial Authorisation for CXD102 in Microsatellite-Stable Colorectal Cancer

Mar 26, 2018

UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.

Celleron Therapeutics appoints Bill Fleming as its Chief Financial Ofﬁcer

Feb 9, 2018

Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Celleron Therapeutics announces EMA COMP Orphan Drug designation for CXD101 in peripheral T-cell lymphoma

Dec 6, 2017

Oxford, UK, 6 December 2017 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced

Celleron Therapeutics announces Licensing and Co-Development Agreement with Nuance Biotech for China and South Africa

Nov 13, 2017

Oxford 13 November 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Dr Chris Towler joins the Board of Celleron Therapeutics

Jul 24, 2017

Oxford 24th July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

CXD101 presented at 3rd Shanghai International Forum

Jul 3, 2017

Oxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Dr. Doug Manion joins Board of Celleron Therapeutics

Jun 1, 2017

Oxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

CXD101 update presented at Inaugural Meeting of Oxford Centre for Cancer Gene Research

Apr 18, 2017

Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Celleron Therapeutics announces completion of a new funding round with international investors

Jan 31, 2017

Oxford 31st January 2017; Celleron Therapeutics Limited, the UK-based precision cancer medicines company, focussed on clinical trials of novel small

Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients

Dec 1, 2015

Oxford, UK, 1st December 2015; Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced that